Optonol was founded in 1996 as a spin off from Medinol. Clinical trials of the Ex-PRESS Miniature Glaucoma Implant began in the last quarter of 1996. Optonol was granted a CE mark and ISO 9001 certification in January 1999, allowing it to market its Ex-PRESS in the European Union.
Optonol first product in this area is a unique microscopic implant that redefines the surgical treatment for patients with medically uncontrolled glaucoma. Optonol's ability to manufacture such precision devices has opened a variety of new applications addressing other diseases where specific designed micro-implants are the only solution. Optonol is committed to the development of simple solutions using advanced technology to help reduce human suffering and improve quality of life.
The Ex-PRESS(TM) miniature glaucoma implant acts as a shunt to modulate drainage of intraocular fluids, thus reducing intraocular pressure. The Ex-PRESS has been shown clinically to be a safe surgical device with low complication rates. Its surgical results demonstrate the benefits of a less invasive approach to filtering surgery. Most significantly, by lowering the post operative inflammatory response, surgeons are seeing earlier patient recovery. Additionally, the need for medications is virtually eliminated in the majority of cases involving the Ex-PRESS shunt.
The device has regulatory approvals in Europe, Canada, and the USA.
Ira Yaron (Chief Executive Officer)
Mr. Yaron has engineering/technological education and experience in executive positions in high-tech companies such as Orbotech and Medinol.
Dan Gazit (Chief Financial Officer and Vice President Business Development)
Mr. Gazit has extensive experience in finance, public offerings and capital raising in Israel, Europe and the US. Joined Optonol in July 2005. Previous companies include Card Guard, Neuromedical Systems and Orbot.
Oded Nissan (Vice President R&D & Manufacturing)
Mr. Nissan has an extensive R&D and Engineering experience in the fields of Medical devices, Materials and Industrial Automation. He has a B.Sc in Mechanical Engineering and M.Sc. In Mechanical-Materials Engineering. Joined Optonol in 2000. Previous companies include Brainsgate, Nicast, and Ashrad Systems.
Patrick H. King (Vice President Sales USA)
Mr. King has an extensive Sales & Marketing experience in Ophthalmology in the USA. He has a business degree from Loras College, Iwoa, USA. Mr. King joined Optonol in June 2006. He served in International positions in the following companies: CooperVision, VisiJet, CIBA Vision and Mentor Corp.
Taoufiq Jellal (Vice President Sales Europe, The Middle East & Africa)
Mr. Jellal has an extensive Sales & Marketing experience in Ophthalmology in Europe the Middle East and Africa. He has a Business degree from the Hamburg High school of commerce and a Master degree in Sociology form the University of Paris, France. Mr. Jellal joined Optonol in January 2007. He served in International positions in the following companies: Iridex Corporation, Heidelberg engineering, Allergan and Storz.
Jason McCabe (Vice President Sales Asia-Pacific)
Mr. McCabe has an extensive Sales & Marketing experience in Ophthalmology in Asia and the Pacific region. He has a degree in Business Law and Communication from the Newcastle College of Advanced Education, Newcastle, Australia. Mr. McCabe joined Optonol in October 2006. He served in International positions in the following companies: Bausch & Lomb, Norwood Eye Care, Ellex Medical and Allergan.
Maital Ben-Hur (Director of Clinical Activities)
Ms. Ben-Hur holds a B. Sc. degree in Pharmacy and has clinical and regulatory experience in medical device companies. Joined Optonol in 2000. Previous companies include SuperDimension and Mindguard.
Robert E. Ryan (Director of Sales USA)
Mr. Ryan has an extensive Sales & Marketing experience in Ophthalmology in the USA. He holds a B.A. from Rutgers University, New Jersey, USA. Mr. Ryan joined Optonol in June 2006. He served in International positions in the following companies: MIRA, Ciba Vision and Mentor Corporation.